Based on the Deciphera Pharmaceuticals LLC stock forecast from 5 analysts, the average analyst target price for Deciphera Pharmaceuticals LLC is USD 22.40 over the next 12 months. Deciphera Pharmaceuticals LLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Deciphera Pharmaceuticals LLC is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Deciphera Pharmaceuticals LLC’s stock price was USD 14.18. Deciphera Pharmaceuticals LLC’s stock price has changed by -0.35% over the past week, -7.32% over the past month and -2.34% over the last year.
No recent analyst target price found for Deciphera Pharmaceuticals LLC
No recent average analyst rating found for Deciphera Pharmaceuticals LLC
Company Overview Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Read Less
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationall...Read More
Frequently Asked Questions About Deciphera Pharmaceuticals LLC (DCPH) Stock
Based on ratings from 5 analysts Deciphera Pharmaceuticals LLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on DCPH's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for DCPH is USD 22.40 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 14.
DCPH stock's Price/Earning ratio is 4.30.
Our analysis grades DCPH stock's Price / Earning ratio at C. This means that DCPH stock's Price/Earning ratio is above 24% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this DCPH may be undervalued for its sector.
The last closing price of DCPH's stock was USD 14.18.
The most recent market capitalization for DCPH is USD 1.23B.
Based on targets from 5 analysts, the average taret price for DCPH is projected at USD 22.40 over the next 12 months.
This means that DCPH's stock price may go up by +57.97% over the next 12 months.
We can't find any ETFs which contains Deciphera Pharmaceuticals LLC's stock.
As per our most recent records Deciphera Pharmaceuticals LLC has 355 Employees.
Deciphera Pharmaceuticals LLC's registered address is 200 Smith Street, Waltham, MA, United States, 02451.
You can get more information about it from Deciphera Pharmaceuticals LLC's website at https://www.deciphera.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DCPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
